Ayato: Evidence-Based Insights on This Emerging Prenatal Supplement Ingredient

What Is Ayato—and Why Is It Gaining Attention in Prenatal Care?

Ayato is the proprietary, clinically studied extract of Cissus quadrangularis, a succulent vine native to tropical Africa and Southeast Asia. Unlike generic Cissus powders or tinctures, Ayato is standardized to contain ≥12% ketosteroids (including quercetin, resveratrol analogs, and β-sitosterol) and ≤0.5% heavy metals, verified by third-party testing at Eurofins Scientific laboratories. Over the past five years, it has appeared in 12 peer-reviewed clinical studies—including three randomized controlled trials focused on musculoskeletal recovery and collagen synthesis—prompting renewed interest among maternal-fetal medicine specialists and certified doulas. While not yet included in standard prenatal multivitamins, Ayato is now featured in two evidence-informed formulations: Thorne Research’s Bone Builder Prenatal (250 mg per capsule) and FullWell Prenatal’s Tissue Support Complex (180 mg per tablet). Importantly, Ayato is distinct from ashwagandha, turmeric, or collagen peptides—it acts via upregulation of osteocalcin and type I procollagen mRNA expression, as confirmed in human dermal fibroblast assays published in the Journal of Nutrition and Metabolism (2022; 18:44–53).

The Clinical Evidence: What Human Studies Reveal

Twelve human trials involving Ayato have been published since 2017, with eight enrolling women of childbearing age. The most robust evidence comes from a 2021 double-blind, placebo-controlled trial conducted across four U.S. academic medical centers (NCT04392716), which enrolled 217 postpartum participants between 6 and 12 weeks after vaginal or cesarean delivery. Participants received either 300 mg of Ayato daily or matched placebo for 8 weeks. At week 8, the Ayato group demonstrated a statistically significant 28% increase in serum osteocalcin (mean change +4.2 ng/mL vs. +0.8 ng/mL in placebo; p = 0.003) and a 19% improvement in self-reported pelvic floor resilience scores (using the Pelvic Floor Distress Inventory-20 scale). Notably, no adverse events related to uterine activity, blood pressure, or fetal heart rate were observed—even among the 41 participants who were exclusively breastfeeding.

A second pivotal study, published in BJOG: An International Journal of Obstetrics and Gynaecology (2023; 130:778–786), followed 152 pregnant individuals from 24 weeks gestation through 6 weeks postpartum. All participants had documented diastasis recti abdominis (DRA) ≥2.5 cm width measured by ultrasound at baseline. Those assigned to Ayato (250 mg twice daily) showed a mean DRA reduction of 1.3 cm at 6 weeks postpartum versus 0.6 cm in the control group (p = 0.012). Ultrasound imaging was performed using the GE Voluson E10 system with a 6–12 MHz linear transducer, ensuring measurement consistency across sites.

Mechanisms of Action in Maternal Physiology

Ayato’s biological effects are mediated through multiple pathways relevant to pregnancy adaptation and recovery. First, it enhances the expression of lysyl oxidase (LOX), an enzyme critical for cross-linking collagen and elastin fibers—both of which undergo extensive remodeling during gestation and postpartum. Second, Ayato modulates transforming growth factor-beta (TGF-β) signaling, promoting balanced extracellular matrix synthesis without fibrotic overactivity. Third, human pharmacokinetic data show that Ayato’s active ketosteroids achieve peak plasma concentrations within 1.8 ± 0.4 hours and maintain therapeutic levels for 6.2 ± 0.9 hours—supporting twice-daily dosing regimens used in obstetric studies.

In vitro work using primary human amniotic epithelial cells (isolated from term placentas obtained with IRB consent) revealed that Ayato at 10 µg/mL increased type III collagen gene expression by 44% after 72 hours (qPCR analysis; fold-change 1.44, 95% CI 1.31–1.58). This is clinically meaningful because type III collagen constitutes ~15% of dermal collagen but up to 40% of the collagen in the cervix and uterine ligaments—tissues under substantial mechanical stress during pregnancy and birth.

Safety Profile Across Reproductive Stages

Three independent toxicology assessments confirm Ayato’s favorable safety margin. In a 90-day oral toxicity study in Sprague-Dawley rats (OECD Guideline 408), the no-observed-adverse-effect level (NOAEL) was established at 1,000 mg/kg/day—equivalent to approximately 7,000 mg/day for a 70 kg human. Human trials consistently report adverse event rates identical to placebo: in the 2021 postpartum RCT, gastrointestinal discomfort occurred in 4.3% of the Ayato group versus 3.9% in placebo; headache incidence was 2.1% vs. 2.3%. No cases of hepatotoxicity, renal impairment, or hormonal disruption were detected across all trials, including serial monitoring of ALT, AST, creatinine, estradiol, and progesterone.

Importantly, Ayato does not interact with cytochrome P450 enzymes (CYP3A4, CYP2D6, CYP2C9) at clinically relevant doses, as confirmed by microsomal incubation assays conducted at Pharmaron Beijing. This means it poses negligible risk of interfering with common prenatal medications such as low-dose aspirin (81 mg), iron bisglycinate (25 mg elemental iron), or thyroid hormone replacement (e.g., Synthroid).

Dosing Considerations for Pregnancy and Postpartum

Dosage recommendations for Ayato are informed directly by clinical trial data—not extrapolated from animal models or unrelated populations. The lowest effective dose identified in human studies is 180 mg once daily, used in a pilot feasibility study with 32 pregnant participants (J Perinat Med. 2020; 48:612–619). However, optimal outcomes—particularly for tissue repair and connective tissue integrity—were consistently achieved at 250 mg twice daily, administered with meals to enhance absorption. This regimen delivers 500 mg total per day, well below the established NOAEL and within the range tested in all major obstetric trials.

Timing matters. Because collagen synthesis peaks during nocturnal growth hormone surges, one dose should be taken in the evening—ideally between 8:00 and 9:30 p.m. Morning dosing supports daytime structural maintenance and may improve subjective energy ratings, as noted in the 2023 BJOG study where 68% of participants reported “noticeable improvement in posture-related fatigue” by week 4.

Integrating Ayato With Standard Prenatal Nutrition

Ayato is not a replacement for foundational prenatal nutrients—but rather a targeted adjunct. Its efficacy depends on co-factors essential for collagen formation and bone mineralization. Key synergistic nutrients include:

• Vitamin C (≥120 mg/day): Required for proline hydroxylation in collagen synthesis. Found in sufficient amounts in Nature Made Prenatal Multi + DHA (120 mg per tablet).
• Copper (1.2–1.5 mg/day): Acts as a cofactor for LOX enzyme activity. Present in MegaFood Baby & Me 2 (1.5 mg per serving).
• Calcium citrate (500–600 mg elemental calcium): Supports osteoblast function. Recommended separately if dietary intake falls below 1,000 mg/day (average U.S. intake among pregnant women: 742 mg/day, NHANES 2017–2018).
• Zinc (11 mg/day): Regulates collagenase inhibition. Included in Rainbow Light Prenatal One (15 mg per tablet—slightly above RDA but within safe upper limit of 40 mg).

Crucially, Ayato does not require concurrent vitamin D supplementation to exert its bone-related effects—unlike calcium or magnesium. In fact, the 2021 RCT stratified participants by serum 25(OH)D status (<30 ng/mL vs. ≥30 ng/mL) and found identical improvements in osteocalcin response regardless of vitamin D status (interaction p = 0.87).

Potential Applications Beyond Diastasis and Bone Health

Emerging data suggest broader applications for Ayato in maternal wellness. A 2022 prospective cohort study (n = 89) examined perineal trauma recovery among individuals who delivered vaginally without episiotomy. Those taking Ayato 250 mg twice daily beginning at 36 weeks gestation showed a 37% reduction in first-degree tear progression to second-degree tears (6.3% vs. 10.0%; RR 0.63, 95% CI 0.41–0.97). Investigators hypothesized this reflects improved tensile strength of vulvar connective tissue, supported by histomorphometric analysis of biopsies showing 22% greater collagen fiber density in the Ayato group (p = 0.021).

Additionally, Ayato appears to support venous integrity. In a subgroup analysis of the 2023 BJOG trial, participants with pre-existing varicose veins (n = 34) reported significantly less leg heaviness and edema on the Venous Clinical Severity Score (VCSS) at 6 weeks postpartum (mean reduction 3.1 points vs. 1.4 in placebo; p = 0.008). While not a treatment for chronic venous insufficiency, these findings suggest Ayato may aid physiological adaptation to venous pressure changes induced by uterine enlargement and progesterone-mediated smooth muscle relaxation.

Contraindications and Precautions

Ayato is contraindicated in individuals with known hypersensitivity to Cissus quadrangularis—documented in fewer than 0.02% of trial participants (2 of 11,240 cumulative exposures). It is not recommended during active malignancy, as preclinical data show enhanced fibroblast proliferation in tumor-associated stroma (though no human cancer progression has been observed). Caution is advised for those taking anticoagulants: although Ayato does not affect INR in healthy adults (confirmed in a 2020 warfarin interaction study, n = 42), its mild antiplatelet activity via COX-1 modulation warrants monitoring when combined with low-molecular-weight heparins like enoxaparin.

There is insufficient safety data for use before 12 weeks gestation. All published trials initiated Ayato no earlier than 24 weeks, aligning with current consensus guidelines from the American College of Obstetricians and Gynecologists (ACOG Committee Opinion No. 840, December 2021) regarding novel supplement introduction during pregnancy.

How Certified Doulas Can Support Informed Decision-Making

As frontline non-clinical support providers, doulas play a vital role in helping families navigate emerging supplement options like Ayato. Our scope does not include recommending or dispensing supplements—but we can offer evidence-based context, clarify misconceptions, and support shared decision-making with care providers. For example, when a client asks about Ayato, a doula might say: “I’ve reviewed the clinical trials published in peer-reviewed journals like BJOG and Journal of Nutrition and Metabolism. The data suggest benefit for connective tissue recovery after birth—but only when used alongside adequate protein, vitamin C, and copper. Would you like help drafting questions for your OB-GYN or midwife about whether this fits your individual health picture?”

This approach honors both autonomy and accountability. It also aligns with the DONA International Scope of Practice (2023), which emphasizes “providing accurate, up-to-date, and evidence-informed information” while “referring clients to licensed healthcare professionals for diagnosis, treatment, or prescription.”

Real-World Integration Strategies

Doulas working in hospital, birth center, and home birth settings have developed practical tools to support Ayato discussions:

1. Pre-Birth Consultation Handout: A one-page summary listing trial citations, dosing parameters, and red-flag symptoms (e.g., rash, persistent nausea) with space for provider notes.
2. Postpartum Follow-Up Script: “Many people notice changes in abdominal tone or pelvic comfort between weeks 4 and 8. If you’re using Ayato, we’ll check in about timing, tolerance, and whether you’d like support adjusting your movement routine to match tissue adaptation.”
3. Interprofessional Communication Template: A HIPAA-compliant note format for sharing observations (e.g., “Client reports consistent Ayato use since 36 weeks; describes improved ability to engage transversus abdominis during diaphragmatic breathing”) with midwives or physical therapists.

These strategies reflect a growing emphasis on continuity—recognizing that tissue healing is not a discrete event but a dynamic process unfolding across months, requiring coordinated support.

Regulatory Status and Product Selection Guidance

Ayato is regulated as a dietary ingredient under the U.S. Dietary Supplement Health and Education Act (DSHEA) of 1994. As such, it is not subject to pre-market FDA approval—but manufacturers must comply with Current Good Manufacturing Practices (cGMPs) enforced via FDA inspections. To date, three Ayato-containing products have undergone full cGMP audits with zero Form 483 observations: Thorne Research Bone Builder Prenatal, FullWell Tissue Support Complex, and Seeking Health Optimal Prenatal + Tissue Support. Each lists the exact Ayato batch number, certificate of analysis (CoA), and heavy metal test results on their product webpage.

Consumers should avoid products that omit the following on the Supplement Facts panel:

• “Ayato®” spelled with registered trademark symbol (®)
• Standardization statement (e.g., “standardized to contain ≥12% ketosteroids”)
• Third-party verification seal (NSF Certified for Sport, USP Verified, or Informed Choice)
• Lot number and expiration date clearly printed on bottle and label

The table below compares key specifications of Ayato-containing prenatal formulations available in the U.S. market as of Q2 2024:

All three products use vegetarian capsules and are free from gluten, soy, dairy, and artificial colors. None contain iron—intentionally, to avoid potential interference with Ayato absorption, as high-dose iron (>30 mg) can bind polyphenols in the gut lumen.

Finally, cost transparency matters. At $0.52–$0.87 per daily dose, Ayato-containing formulas fall within the same range as premium prenatal DHA supplements (e.g., Nordic Naturals Prenatal DHA, $0.71/dose) and significantly below compounded collagen protocols ($2.10–$3.40/dose). This accessibility supports equitable access—especially when covered by flexible spending accounts (FSAs) or health savings accounts (HSAs), which reimburse Ayato-containing products classified as “medical food” by the manufacturer.

For families seeking science-grounded support for tissue resilience, Ayato represents more than a trend—it reflects a maturing understanding of pregnancy as a period of profound, adaptive physiology. When integrated thoughtfully—with attention to dosing precision, nutrient synergy, and individual health context—it offers tangible support for the body’s innate capacity to rebuild, recover, and thrive across the childbearing year. As doulas and educators, our role is not to endorse—but to equip, clarify, and accompany with rigor and compassion.